Background. The clinical importance of point mutations of ras oncogene in differentiated
thyroid cancers has not been fully clarified. The purpose of this study is to determine the …

Codon 61 of the N-ras oncogene was screened for mutations in 99 surgically resected
thyroid carcinomas by a polymerase chain resection (PCR)-based method (PCR-primer …

Current models for tumorigenesis propose that a series of genetic alterations occur during
the progression from the normal cell to the malignant phenotype. Mutations in each of the …

Purpose: ras oncogenic activation has long been demon-strated in thyroid carcinomas of
follicular cell derivation, but no consistent relationship has been shown between mutations …

The histological differentiation of thyroid carcinoma is known to correlate with prognosis.
Ras oncogene mutations, which have been identified in various human cancers, have been …

Ras mutations have been found in thyroid lesions. Different studies have shown different
frequencies of mutations among benign and malignant lesions. The presence of point …

Mutations in the ras genes (H-ras, K-ras, and N-ras) occur in 10–15% of all human cancers,
and commonly arise from single base substitutions at codons 12, 13, or 61. Although ras …

Using the method of polymerase chain reaction‐single strand conformation polymorphism,
the point mutations of the ras oncogenes in a total of 33 thyroid tissues, including 12 …

Using polymerase chain reaction and sequence-specific oligonucleotide hybridization, the
frequency of three ras oncogene mutations (N-ras, Ha-ras, and K-ras) in thyroid tumors (25 …

In a small initial study of oncogene activation in differentiated thyroid cancer, using DNA
transfection and tumor-igenicity assays, we identified activating ras mutations in 80%(4/5) of …